As of 2025-07-11, the EV/EBITDA ratio of ANI Pharmaceuticals Inc (ANIP) is -52.46. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ANIP's latest enterprise value is 1,904.09 mil USD. ANIP's TTM EBITDA according to its financial statements is -36.30 mil USD. Dividing these 2 quantities gives us the above ANIP EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.1x - 10.0x | 9.6x |
| Forward P/E multiples | 10.4x - 10.6x | 10.4x |
| Fair Price | (37.07) - (15.66) | (26.89) |
| Upside | -156.1% - -123.7% | -140.7% |
| Date | EV/EBITDA |
| 2025-07-10 | -52.46 |
| 2025-07-09 | -51.99 |
| 2025-07-08 | -51.84 |
| 2025-07-07 | -51.75 |
| 2025-07-03 | -51.97 |
| 2025-07-02 | -51.93 |
| 2025-07-01 | -50.94 |
| 2025-06-30 | -51.95 |
| 2025-06-27 | -52.10 |
| 2025-06-26 | -52.28 |
| 2025-06-25 | -52.34 |
| 2025-06-24 | -52.98 |
| 2025-06-23 | -52.42 |
| 2025-06-20 | -52.13 |
| 2025-06-18 | -51.60 |
| 2025-06-17 | -50.82 |
| 2025-06-16 | -51.38 |
| 2025-06-13 | -50.35 |
| 2025-06-12 | -50.08 |
| 2025-06-11 | -50.48 |
| 2025-06-10 | -50.53 |
| 2025-06-09 | -50.72 |
| 2025-06-06 | -49.99 |
| 2025-06-05 | -48.75 |
| 2025-06-04 | -49.34 |
| 2025-06-03 | -49.81 |
| 2025-06-02 | -49.96 |
| 2025-05-30 | -48.06 |
| 2025-05-29 | -47.78 |
| 2025-05-28 | -47.51 |
| 2025-05-27 | -47.82 |
| 2025-05-23 | -47.50 |
| 2025-05-22 | -47.19 |
| 2025-05-21 | -48.27 |
| 2025-05-20 | -49.20 |
| 2025-05-19 | -48.91 |
| 2025-05-16 | -48.81 |
| 2025-05-15 | -48.54 |
| 2025-05-14 | -49.04 |
| 2025-05-13 | -50.01 |
| 2025-05-12 | -50.19 |
| 2025-05-09 | -52.58 |
| 2025-05-08 | -55.70 |
| 2025-05-07 | -55.27 |
| 2025-05-06 | -54.94 |
| 2025-05-05 | -56.31 |
| 2025-05-02 | -56.54 |
| 2025-05-01 | -55.19 |
| 2025-04-30 | -55.27 |
| 2025-04-29 | -55.24 |